Compare Nasdaq Inc (NDAQ) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nasdaq Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Nasdaq Inc trades at $94.92 (market cap $53.11B), while Vertex Pharmaceuticals Incorporated trades at $527.4 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.5× Nasdaq Inc's market cap, and Nasdaq Inc pays a 1.22% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| NDAQ | VRTX | |
|---|---|---|
Market Cap | $53.11B | $134.25B |
Sector | Financials | Health |
52-Week High | $100.98 | $529.65 |
52-Week Low | $76.85 | $376.62 |
Enterprise Value | $59.57B | $128.37B |
Dividend Yield | 1.22% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nasdaq (NDAQ) trades at $95.62, up 1.09% today, with strong technical momentum and consistent earnings beats. Revenue grew to $8.26B in 2025, with net income margin expanding to 22.52%. The company announced the acquisition of LeveL Markets, advancing its always-on markets strategy, and maintains a bullish analyst consensus.
Outlook remains positive with a consensus price target of $109.20, offering ~14% upside. Risks include market volatility sensitivity and integration challenges from acquisitions. Solid profitability and strategic growth initiatives support a favorable investment case, though macroeconomic headwinds warrant monitoring.
Vertex Pharmaceuticals (VRTX) trades at $523.91, up 5.61% with strong technical momentum and bullish moving averages. The company reported Q2 2026 revenue growth of 12% to $3.3 billion, beating expectations despite an EPS miss, and raised its full-year 2026 revenue guidance. Valuation metrics show a P/E of 30.85 and P/S of 10.78, while maintaining robust profitability with 86% gross margins and 35% net income margins.
Outlook remains positive with analyst consensus strongly bullish (84% buy ratings) and a $534.25 price target. Key risks include execution on newer product launches and competitive pressures in cystic fibrosis treatments. The stock's current momentum suggests continued upside potential, though RSI levels indicate potential near-term overbought conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
